Grants8

Grant Information	Key Details	Eligibility & Funding
Wsparcie firm w okresowych trudnościach – oferta dla przedsiębiorców FERS 01.03 Programme: Fundusze Europejskie dla Rozwoju Społecznego 2021-2027	Core objective: To provide non-financial support, primarily through training and consulting services, to micro, small, and medium-sized enterprises (MŚP) in Poland that are experiencing or are at risk of temporary operational difficulties or economic crisis. Explicit identification of target recipient type and size: Micro, Small, and Medium Enterprises (MŚP), including self-employed individuals. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-AGNOSTIC. Geographic scope and any location requirements: Poland. The applicant's main office or permanent place of business must be located within the territory of the Republic of Poland. Key filtering criteria for initial grant screening: MŚP status, active business for at least 12 months, and a 'warning level' result from the mandatory PARP Self-Diagnosis (Autodiagnoza) tool. Grant frequency and program context: This is a recurring opportunity part of the broader 'Fundusze Europejskie dla Rozwoju Społecznego 2021-2027' (European Funds for Social Development 2021-2027) program, specifically Action 01.03 'Kadry nowoczesnej gospodarki' (Human Resources for a Modern Economy). Applications are continuously accepted by selected operators.	Funding Up to 154384.00 PLN Deadline April 30, 2027, 11:59 p.m.	Details
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) PAR-25-270 Programme: National Institutes of Health (NIH) - National Center for Complementary and Integrative Health (NCCIH)	This grant encourages investigator-initiated, early phase clinical trials of natural products to determine if further clinical testing is warranted. It targets research institutions, non-profits, for-profits, and government entities capable of conducting rigorous clinical trials. SECTOR-SPECIFIC: Focuses on complementary and integrative health, specifically natural products (botanicals, dietary supplements, probiotics, nutritional regimens). Geographic scope: Organizations in the US. Foreign components are allowed (collaborators/consultants) but foreign sites outside the US or Canada are not eligible. Key filtering criteria: Must propose an early phase clinical trial, involve natural products, demonstrate target engagement, and explicitly exclude cancer treatment/prevention trials. Grant frequency: Recurring, with multiple application deadlines through October 2026. Program context: An R33 Exploratory/Developmental Grants Phase II mechanism from NCCIH, part of the National Institutes of Health (NIH).	Funding Up to 1050000.00 USD Deadline Oct. 20, 2026, 5 p.m.	Details
Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed) RFA-HL-26-017 Programme: Catalyze Innovation Program (National Heart, Lung, and Blood Institute - NHLBI)	• Core objective: This grant aims to provide early-stage translational support for developing potential therapeutic candidates (small molecules, biologics, and combination products) to treat heart, lung, blood, and sleep (HLBS) diseases and disorders, progressing from target identification to preliminary product/lead series identification. • Target recipients: Researchers, higher education institutions, non-profits, for-profit organizations (including small businesses), and government entities engaged in therapeutic product definition and preclinical development. • SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on health and medical research, particularly within cardiology, pulmonology, hematology, and sleep medicine, with emphasis on therapeutic product development. • Geographic scope: Organizations based in the United States, including U.S. territories. Foreign organizations are not eligible. • Key filtering criteria: Focus on HLBS diseases and disorders, early-stage therapeutic development (pre-clinical, no clinical trials), and requirement for a phased (R61/R33) approach with defined milestones. • Grant frequency: Recurring, with multiple application deadlines through October 2027, as part of the broader NHLBI Catalyze innovation program.	Funding Up to 400000.00 USD Deadline Oct. 21, 2027, 5 p.m.	Details
Fostering animal breeding and genetics for climate change adaptation and mitigation, improved robustness and resilience HORIZON-CL6-2025-02-FARM2FORK-07 Programme: Horizon Europe	Core Objective: To foster animal breeding and genetics to improve livestock robustness and resilience, and to contribute to climate change adaptation and mitigation efforts. Target Recipient Type and Size: Open to a wide range of organizations, including research institutions, universities, SMEs, enterprises, NGOs, and public bodies. The 'multi-actor approach' requires diverse participation, including farmers, breeders, advisors, private sector, industry, and policymakers. No specific size limitations are mentioned, encouraging participation from all sizes of eligible entities. Designation: SECTOR-SPECIFIC (Agriculture, Livestock, Environment, Research). Geographic Scope: Primarily EU Member States and Associated Countries. International cooperation is encouraged. Key Filtering Criteria: Focus on animal breeding and genetics for environmental benefits, particularly climate change mitigation (e.g., reducing greenhouse gas emissions) and adaptation. Projects must involve a 'multi-actor approach' and demonstrate practical applications (TRL 7). Grant Frequency and Context: This is a specific topic under the HORIZON-CL6-2025-02 call within Horizon Europe, which is a recurring framework program for research and innovation (2021-2027).	Funding Up to 6000000.00 EUR Deadline Sept. 16, 2025, midnight	Details
Startup Booster Poland – Smart UP – oferta dla startupów Startup Booster Poland – Smart UP Programme: European Funds for a Modern Economy 2021-2027, Priority FENG.02 Environment supporting innovation, Measure FENG.02.28 Startup Booster Poland – Smart UP	The 'Startup Booster Poland – Smart UP' program aims to support innovative businesses in their early stages of development. It provides funding and acceleration programs to help startups develop their products or accelerate their growth. - Target recipients: Startups, micro and small enterprises. - SECTOR-AGNOSTIC (with options for sector-specific acceleration via partner accelerators). - Geographic scope: Project implementation in Poland, with international expansion possible through 'Go Global' paths. - Key filtering criteria: Early-stage innovative enterprises, meeting specific SME/startup definitions, selected through accelerator criteria. - Grant frequency: Recurring program, with application rounds managed by individual accelerators, operating under a broader program timeframe.	Funding Up to 400000.00 PLN Deadline Oct. 31, 2026, midnight	Details
Smart integration of net zero technologies into Energy Intensive industries (Processes4Planet and Made in Europe partnerships) (IA) 48400412TOPICSen Programme: Horizon Europe	To accelerate the deployment of net-zero technologies through smart integration in energy intensive industries, fostering collaboration across the value chain to enhance European competitiveness and decarbonisation. - Target recipient type and size: 'Legal entities' are eligible, implying businesses (SME, Enterprise), research organisations, and potentially public bodies in consortia. Focus on 'manufacturers of net-zero technology solutions', 'energy intensive industries', 'engineering and construction firms'. - SECTOR-SPECIFIC: Energy Intensive Industries, Manufacturing, Energy, Environment. - Geographic scope and any location requirements: European Union Member States and Associated Countries. Legal entities established in China are explicitly excluded. - Key filtering criteria for initial grant screening: Projects must focus on smart integration of net-zero technologies in energy-intensive industries, require collaborative efforts (consortia), demonstrate readiness for deployment (TRLs 6-7), and present a strong business and exploitation strategy. - Grant frequency and program context: This is a single-stage call within the Horizon Europe Framework Programme, specifically under Cluster 4 (Digital, Industry and Space) Work Programme 2025. It aligns with the EU's twin green and digital transition goals for industrial leadership.	Funding Up to 9000000.00 EUR Deadline Sept. 23, 2025, midnight	Details
Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed) PAR-25-092 Programme: National Institutes of Health (NIH)	Core objective: Support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to enable secondary analysis by the scientific community. Target recipient: Eligible organizations include Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), Local Governments, Federal Governments, and other entities like Independent School Districts and Faith-based Organizations, all capable of managing and sharing scientific data. SECTOR-SPECIFIC Geographic scope: Organizations based in the United States are eligible. Foreign entities are not eligible, but foreign components within a U.S. organization's application may be allowed. Key filtering criteria: Projects must focus on child health and human development data, involve archiving existing data (data collection must be complete), and are not permitted to include clinical trials. The maximum direct costs are $50,000 per year. Grant frequency: This is a reissue (PAR-25-092 reissues PAR-24-256), indicating it is a recurring funding opportunity that supports data sharing within NIH's broader scientific mission.	Funding Up to 100000.00 USD Deadline Nov. 16, 2025, 10 p.m.	Details
From heat-driven processes to the use of mechanical and electric forces (Processes4Planet partnership) (IA) HORIZON-CL4-INDUSTRY-2025-01-TWIN-TRANSITION-31 Programme: Horizon Europe	The core objective of this grant is to support the transition of energy-intensive process industries from traditional heat-driven methods to innovative electrically-driven processes. This aims to significantly reduce Greenhouse Gas (GHG) emissions, achieve substantial energy savings, and enhance the economic viability and resilience of the European process industry. - Explicit identification of target recipient type: Legal entities operating within energy-intensive and process industries, as well as research organizations and universities contributing to industrial innovation. - SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC, targeting Energy-Intensive Industries, Process Industries, and Manufacturing. - Geographic scope: Projects with impact across the European industry, aligning with EU climate neutrality goals. Eligible participants are from EU Member States and countries associated with Horizon Europe, with a specific exclusion for entities established in China. - Key filtering criteria for initial grant screening: Projects must focus on electrically-driven technologies to replace heat input, demonstrate strong potential for GHG emission avoidance and at least 25% energy savings, and provide a clear business case for European deployment. - Grant frequency: This specific topic is part of the Horizon Europe Work Programme 2025 and is a single-stage call for proposals, with calls under the broader Horizon Europe framework occurring regularly.	Funding Up to 10000000.00 EUR Deadline Sept. 23, 2025, midnight	Details
NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional) PAR-24-221 Programme: National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Program	This grant aims to support US small businesses in bridging the "Valley of Death" funding gap for neurological disease treatments, tools, and diagnostics. It targets small businesses that have previously received an NIH SBIR or STTR Phase II award, allowing them to pursue advanced clinical trials (Phase 1 or 2) or develop complex research tools towards commercialization. This is a SECTOR-SPECIFIC grant focused on neurological disorders and related medical biotechnology. Geographic scope is limited to the United States for eligible small business concerns, though project activities may include foreign components. Key filtering criteria include prior NIH SBIR/STTR Phase II funding, status as a US Small Business Concern, and focus on clinical trials or research tools for neurological conditions. This is a recurring grant opportunity with multiple application due dates until April 2027, reissued from a previous program.	Funding Up to 3000000.00 USD Deadline April 5, 2027, 5 p.m.	Details
Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional) PAR-25-318 Programme: National Institute on Deafness and Other Communication Disorders (NIDCD) Research Grant Program	This grant aims to stimulate exploratory and developmental HIV/AIDS research focused on hearing, balance, taste, smell, voice, speech, and language disorders, specifically benefiting people living with HIV. The grant targets a wide range of organizations, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities, of unspecified size, capable of conducting research. This is a SECTOR-SPECIFIC grant with a global geographic scope. Key filtering criteria include: research must be HIV/AIDS related and fall within NIDCD's mission areas (communication disorders), must address high-priority NIH Office of AIDS Research (OAR) areas, and only low-risk clinical trials are supported. This is a recurring funding opportunity (reissue of PAR-23-106) for exploratory/developmental research (R21 activity code) within the National Institutes of Health (NIH) framework.	Funding Up to 275000.00 USD Deadline Jan. 7, 2028, 5 p.m.	Details
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) PAR-25-103 Programme: National Institutes of Health (NIH) - National Cancer Institute (NCI)	Core Objective: To facilitate well-planned clinical trials across the cancer prevention and control spectrum by supporting studies that acquire critical data to complete the protocol of a full-scale multi-center Phase II or later phase trial. Target Recipient Type and Size: Open to a wide range of organizations including higher education institutions, nonprofits (both 501(c)(3) and others), for-profit organizations (including small businesses), local and federal governments, and non-domestic (foreign) entities. There are no explicit size restrictions, focusing on organizational capacity for clinical research planning. SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC, focusing exclusively on cancer prevention and control clinical trials and related research activities. Geographic Scope: Worldwide, as non-domestic (non-U.S.) entities are eligible to apply. Key Filtering Criteria: The grant is for planning activities for future clinical trials, not for conducting full trials or early-stage mechanistic research. Applicants must have preliminary efficacy or effectiveness data for the future intervention already in existence. Proposals must include a detailed milestone plan and a description of the future clinical trial. Grant Frequency and Program Context: This is a recurring funding opportunity with multiple application due dates extending through October 2027, reissued from a previous program (PAR-22-174). It is a U34 Planning Cooperative Agreement, intended to fill a gap in the NCI's funding mechanisms by supporting preparatory studies for robust clinical trials.	Funding Up to 600000.00 USD Deadline Oct. 25, 2027, 5 p.m.	Details
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) PAR-25-199 Programme: National Institutes of Health (NIH)	The core objective is to stimulate basic technology-focused research to develop next-generation human cell-derived Microphysiological Systems (MPS) and related assays. These systems must replicate complex nervous system architectures and physiology with improved fidelity, enabling future studies of development, function, and aging in healthy and disease states. Target recipients are research organizations capable of conducting exploratory/developmental biomedical and biobehavioral research. This grant is SECTOR-SPECIFIC, focusing on the health and technology sectors, specifically neurobiology and bioengineering. Geographic scope includes organizations within the United States and non-U.S. (foreign) entities globally. Key filtering criteria for initial screening: must be focused on MPS technology development for nervous system research, not clinical trials, and not solely focused on compound screening or cell therapy.	Funding Up to 275000.00 USD Deadline Oct. 16, 2025, 5 p.m.	Details
Improving the quality of life of persons with intellectual disabilities and their families 48340142TOPICSen Programme: Horizon Europe	Single, clear statement of grant's core objective: To explore new ways to improve the quality of life, autonomy, and empowerment of persons with intellectual disabilities and their families by developing and implementing innovative medical, technological, and digital solutions, including habilitation and rehabilitation approaches. Explicit identification of target recipient type and size: Legal entities capable of performing Research and Innovation Actions (RIAs). MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Health, Medical, Technology, Social Sciences, Disability Support). Geographic scope and any location requirements: Eligible countries are defined in Annex B of the Work Programme General Annexes. Specifically, legal entities established in the United States of America are eligible to receive Union funding. Key filtering criteria for initial grant screening: Focus on improving quality of life for persons with intellectual disabilities and their families; development of innovative medical, technological, or digital solutions; emphasis on habilitation and rehabilitation; inclusion of social sciences and humanities (SSH) expertise. Grant frequency and program context: Part of the Horizon Europe 2025 Work Programme, specifically within the 'Health' cluster and the 'Staying healthy in a rapidly changing society' destination.	Funding Up to 8000000.00 EUR Deadline April 16, 2026, midnight	Details
Projects Peer Review Panel (PPRP) 2026 – UKRI PPRP 2026 Programme: Projects Peer Review Panel (PPRP)	This grant, the Projects Peer Review Panel (PPRP) 2026, aims to fund large or complex research projects in highly specialized scientific fields. It's designed for UK-based research organizations that have been specifically invited to apply after successfully submitting a Statement of Interest (SoI). This is a SECTOR-SPECIFIC grant, focusing primarily on areas like particle physics, nuclear physics, astronomy, particle astrophysics, accelerator physics, and computing for the PPAN Programme. The grant operates on a recurring basis, with frequent PPRP rounds, forming a core part of the Science and Technology Facilities Council (STFC) funding landscape. The key filtering criteria for initial screening are the requirement for an invitation following a successful SoI, and being an eligible UK research organization focused on the specified scientific domains.	Funding Up to None GBP Deadline Aug. 27, 2026, 4 p.m.	Details
DFG, German Research Foundation - Priority Programmes Priority Programmes Programme: DFG, German Research Foundation - Priority Programmes	This grant, the DFG Priority Programmes, aims to advance science and the humanities by funding new, important research topics through coordinated, multi-location projects. It seeks to foster impactful research, especially interdisciplinary work, by creating added value through networking and supporting early career researchers. The grant is SECTOR-AGNOSTIC regarding specific research fields, but is explicitly focused on scientific and humanities research. It targets research institutions and researchers primarily in Germany. This is a recurring grant program with annual opportunities to propose new Priority Programmes.	Funding Up to None None Deadline Oct. 14, 2026, 11 p.m.	Details
Computing resources on the STFC DiRAC HPC facility (RAC18) RAC18 Programme: STFC DiRAC HPC Facility	This opportunity, known as RAC18, is for UK research organisations within the STFC theory community to apply for and gain access to High Performance Computing (HPC) resources on the DiRAC facility. The core objective is to support world-leading research in specific scientific domains by providing essential computing power and storage. This is a SECTOR-SPECIFIC grant, targeting research in areas such as particle physics, nuclear physics, astrophysics, astronomy, cosmology, solar system physics, and particle astrophysics. The primary target recipients are UK-based research organisations, although overseas organisations approved by STFC may apply. Early career researchers, including postdocs and PhD students, are specifically encouraged to apply as project leads. This is an annual funding call for computing resources, with successful allocations beginning on April 1st, 2026.	Funding Up to None None Deadline Sept. 18, 2025, 3 p.m.	Details
Bundesförderung für Energie- und Ressourceneffizienz in der Wirtschaft (Zuschuss) – Förderung von Transformationsplänen (Modul 5) Modul 5 Programme: Bundesförderung für Energie- und Ressourceneffizienz in der Wirtschaft	Grant Purpose and Target This grant, known as the 'Bundesförderung für Energie- und Ressourceneffizienz in der Wirtschaft (Zuschuss) – Förderung von Transformationsplänen (Modul 5),' aims to support German businesses in their efforts to increase energy and resource efficiency and reduce greenhouse gas emissions. Specifically, Module 5 focuses on funding the creation of transformation plans to help companies achieve greenhouse gas neutrality through strategic investment projects. Core Objective: To empower German companies to develop comprehensive strategies (transformation plans) for enhancing energy and resource efficiency and significantly reducing their greenhouse gas emissions. Target Recipients: This grant is designed for companies (Unternehmen) of all sizes based in Germany. No specific size limitations are mentioned, making it accessible to startups, SMEs, and larger enterprises. Sector Focus: This is a SECTOR-AGNOSTIC grant. While the focus is on energy and resource efficiency, which are critical in many industries, it is not restricted to a single sector. Businesses across various economic activities are encouraged to apply if their projects align with the grant's objectives. Geographic Scope: The grant is applicable nationwide (bundesweit) within Germany. Projects and applicant organizations must be located within Germany. Key Filtering Criteria for Initial Screening: Your business should be a German company actively planning or needing to develop a strategic transformation plan focused on achieving greenhouse gas neutrality and improving energy/resource efficiency. The application must be submitted before you start the actual project. Grant Frequency and Program Context: This grant is part of a larger, ongoing federal funding program. It is a recurring opportunity, available until the end of 2028, indicating a long-term commitment to these goals within the German economy.	Funding Up to None EUR Deadline Dec. 31, 2028, 10:59 p.m.	Details
Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) PAR-25-207 Programme: National Institute of Mental Health (NIMH)	This grant supports definitive clinical trials evaluating the effectiveness of therapeutic and service interventions for the post-acute management of mental health conditions. The core objective is to understand the mechanisms of action, mediators, predictors, and moderators of these interventions to optimize longer-term outcomes for individuals across the lifespan. Eligible recipients include a broad spectrum of organizations: higher education institutions, nonprofits, for-profit organizations (including small businesses), local and federal governments, and various other entities. Organizational size is not defined by employee count, but applicants must demonstrate the capacity to conduct rigorous clinical trials. This grant is SECTOR-SPECIFIC, exclusively focusing on mental health and related healthcare services. Its geographic scope is international, accepting applications from both U.S. and non-U.S. (foreign) entities. Key filtering criteria for initial screening are: a clinical trial is required, the focus must be solely on post-acute mental health interventions, the study must include the examination of mechanisms of action, and it is not for pilot studies or early-stage efficacy testing. This is a recurring R01 Research Project Grant from NIMH, reissuing a previous opportunity, with multiple application windows through October 2027.	Funding Up to None USD Deadline Oct. 5, 2027, 9 p.m.	Details
The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) PAR-25-292 Programme: NIH Research Project Grant	This grant, `The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)`, aims to support innovative population-based research. Its core objective is to identify and characterize how work and occupation influence health outcomes and status, particularly among populations experiencing health and/or healthcare disparities. The grant is SECTOR-SPECIFIC, focusing on public health, social sciences, and healthcare research. It targets organizations conducting research within the U.S. and its territories (including Puerto Rico and the Trust Territory of the Pacific Islands). This is a recurring grant opportunity with multiple application cycles until early 2028, indicating an ongoing program context within the NIH's broader mission to reduce health disparities.	Funding Up to None USD Deadline Oct. 5, 2027, 5 p.m.	Details
Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) PAR-25-326 Programme: National Institutes of Health (NIH)	This opportunity, the Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed), aims to provide investigators with direct, in-kind access to contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS URGenT Network. The core objective is to support planning, manufacturing, and limited nonclinical therapeutic development efforts, as well as other IND-enabling activities, to rapidly advance precision therapeutics for ultra-rare neurological and/or neuromuscular diseases towards clinical trials. This grant is SECTOR-SPECIFIC, focusing intensely on `HEALTHCARE` and `TECHNOLOGY` within the specialized domain of ultra-rare genetic diseases and gene-based therapies. It targets investigators and organizations in the `US` that are developing gene-based or transcript-directed clinical therapeutic candidates. Key filtering criteria include having established proof-of-concept (POC) data and a clear need for pre-IND or IND-enabling support, with the explicit exclusion of clinical trials. This is a recurring funding opportunity with multiple application cycles available through January 2028, forming a continuous mechanism within the broader NINDS URGenT Network to address unmet medical needs for ultra-rare neurological disorders.	Funding Up to None USD Deadline Jan. 31, 2028, 5 p.m.	Details

Wsparcie firm w okresowych trudnościach – oferta dla przedsiębiorców

FERS 01.03

Programme: Fundusze Europejskie dla Rozwoju Społecznego 2021-2027

Core objective: To provide non-financial support, primarily through training and consulting services, to micro, small, and medium-sized enterprises (MŚP) in Poland that are experiencing or are at risk of temporary operational difficulties or economic crisis.
Explicit identification of target recipient type and size: Micro, Small, and Medium Enterprises (MŚP), including self-employed individuals.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-AGNOSTIC.
Geographic scope and any location requirements: Poland. The applicant's main office or permanent place of business must be located within the territory of the Republic of Poland.
Key filtering criteria for initial grant screening: MŚP status, active business for at least 12 months, and a 'warning level' result from the mandatory PARP Self-Diagnosis (Autodiagnoza) tool.
Grant frequency and program context: This is a recurring opportunity part of the broader 'Fundusze Europejskie dla Rozwoju Społecznego 2021-2027' (European Funds for Social Development 2021-2027) program, specifically Action 01.03 'Kadry nowoczesnej gospodarki' (Human Resources for a Modern Economy). Applications are continuously accepted by selected operators.

Funding

Up to 154384.00 PLN

Deadline

April 30, 2027, 11:59 p.m.

Details

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

PAR-25-270

Programme: National Institutes of Health (NIH) - National Center for Complementary and Integrative Health (NCCIH)

This grant encourages investigator-initiated, early phase clinical trials of natural products to determine if further clinical testing is warranted.
It targets research institutions, non-profits, for-profits, and government entities capable of conducting rigorous clinical trials.
SECTOR-SPECIFIC: Focuses on complementary and integrative health, specifically natural products (botanicals, dietary supplements, probiotics, nutritional regimens).
Geographic scope: Organizations in the US. Foreign components are allowed (collaborators/consultants) but foreign sites outside the US or Canada are not eligible.
Key filtering criteria: Must propose an early phase clinical trial, involve natural products, demonstrate target engagement, and explicitly exclude cancer treatment/prevention trials.
Grant frequency: Recurring, with multiple application deadlines through October 2026.
Program context: An R33 Exploratory/Developmental Grants Phase II mechanism from NCCIH, part of the National Institutes of Health (NIH).

Funding

Up to 1050000.00 USD

Deadline

Oct. 20, 2026, 5 p.m.

Details

Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)

RFA-HL-26-017

Programme: Catalyze Innovation Program (National Heart, Lung, and Blood Institute - NHLBI)

• Core objective: This grant aims to provide early-stage translational support for developing potential therapeutic candidates (small molecules, biologics, and combination products) to treat heart, lung, blood, and sleep (HLBS) diseases and disorders, progressing from target identification to preliminary product/lead series identification. • Target recipients: Researchers, higher education institutions, non-profits, for-profit organizations (including small businesses), and government entities engaged in therapeutic product definition and preclinical development. • SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on health and medical research, particularly within cardiology, pulmonology, hematology, and sleep medicine, with emphasis on therapeutic product development. • Geographic scope: Organizations based in the United States, including U.S. territories. Foreign organizations are not eligible. • Key filtering criteria: Focus on HLBS diseases and disorders, early-stage therapeutic development (pre-clinical, no clinical trials), and requirement for a phased (R61/R33) approach with defined milestones. • Grant frequency: Recurring, with multiple application deadlines through October 2027, as part of the broader NHLBI Catalyze innovation program.

Funding

Up to 400000.00 USD

Deadline

Oct. 21, 2027, 5 p.m.

Details

Fostering animal breeding and genetics for climate change adaptation and mitigation, improved robustness and resilience

HORIZON-CL6-2025-02-FARM2FORK-07

Programme: Horizon Europe

Core Objective: To foster animal breeding and genetics to improve livestock robustness and resilience, and to contribute to climate change adaptation and mitigation efforts.
Target Recipient Type and Size: Open to a wide range of organizations, including research institutions, universities, SMEs, enterprises, NGOs, and public bodies. The 'multi-actor approach' requires diverse participation, including farmers, breeders, advisors, private sector, industry, and policymakers. No specific size limitations are mentioned, encouraging participation from all sizes of eligible entities.
Designation: SECTOR-SPECIFIC (Agriculture, Livestock, Environment, Research).
Geographic Scope: Primarily EU Member States and Associated Countries. International cooperation is encouraged.
Key Filtering Criteria: Focus on animal breeding and genetics for environmental benefits, particularly climate change mitigation (e.g., reducing greenhouse gas emissions) and adaptation. Projects must involve a 'multi-actor approach' and demonstrate practical applications (TRL 7).
Grant Frequency and Context: This is a specific topic under the HORIZON-CL6-2025-02 call within Horizon Europe, which is a recurring framework program for research and innovation (2021-2027).

Funding

Up to 6000000.00 EUR

Deadline

Sept. 16, 2025, midnight

Details

Startup Booster Poland – Smart UP – oferta dla startupów

Startup Booster Poland – Smart UP

Programme: European Funds for a Modern Economy 2021-2027, Priority FENG.02 Environment supporting innovation, Measure FENG.02.28 Startup Booster Poland – Smart UP

The 'Startup Booster Poland – Smart UP' program aims to support innovative businesses in their early stages of development. It provides funding and acceleration programs to help startups develop their products or accelerate their growth. - Target recipients: Startups, micro and small enterprises. - SECTOR-AGNOSTIC (with options for sector-specific acceleration via partner accelerators). - Geographic scope: Project implementation in Poland, with international expansion possible through 'Go Global' paths. - Key filtering criteria: Early-stage innovative enterprises, meeting specific SME/startup definitions, selected through accelerator criteria. - Grant frequency: Recurring program, with application rounds managed by individual accelerators, operating under a broader program timeframe.

Funding

Up to 400000.00 PLN

Deadline

Oct. 31, 2026, midnight

Details

Smart integration of net zero technologies into Energy Intensive industries (Processes4Planet and Made in Europe partnerships) (IA)

48400412TOPICSen

Programme: Horizon Europe

To accelerate the deployment of net-zero technologies through smart integration in energy intensive industries, fostering collaboration across the value chain to enhance European competitiveness and decarbonisation. - Target recipient type and size: 'Legal entities' are eligible, implying businesses (SME, Enterprise), research organisations, and potentially public bodies in consortia. Focus on 'manufacturers of net-zero technology solutions', 'energy intensive industries', 'engineering and construction firms'. - SECTOR-SPECIFIC: Energy Intensive Industries, Manufacturing, Energy, Environment. - Geographic scope and any location requirements: European Union Member States and Associated Countries. Legal entities established in China are explicitly excluded. - Key filtering criteria for initial grant screening: Projects must focus on smart integration of net-zero technologies in energy-intensive industries, require collaborative efforts (consortia), demonstrate readiness for deployment (TRLs 6-7), and present a strong business and exploitation strategy. - Grant frequency and program context: This is a single-stage call within the Horizon Europe Framework Programme, specifically under Cluster 4 (Digital, Industry and Space) Work Programme 2025. It aligns with the EU's twin green and digital transition goals for industrial leadership.

Funding

Up to 9000000.00 EUR

Deadline

Sept. 23, 2025, midnight

Details

Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)

PAR-25-092

Programme: National Institutes of Health (NIH)

Core objective: Support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to enable secondary analysis by the scientific community.
Target recipient: Eligible organizations include Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), Local Governments, Federal Governments, and other entities like Independent School Districts and Faith-based Organizations, all capable of managing and sharing scientific data.
SECTOR-SPECIFIC
Geographic scope: Organizations based in the United States are eligible. Foreign entities are not eligible, but foreign components within a U.S. organization's application may be allowed.
Key filtering criteria: Projects must focus on child health and human development data, involve archiving existing data (data collection must be complete), and are not permitted to include clinical trials. The maximum direct costs are $50,000 per year.
Grant frequency: This is a reissue (PAR-25-092 reissues PAR-24-256), indicating it is a recurring funding opportunity that supports data sharing within NIH's broader scientific mission.

Funding

Up to 100000.00 USD

Deadline

Nov. 16, 2025, 10 p.m.

Details

From heat-driven processes to the use of mechanical and electric forces (Processes4Planet partnership) (IA)

HORIZON-CL4-INDUSTRY-2025-01-TWIN-TRANSITION-31

Programme: Horizon Europe

The core objective of this grant is to support the transition of energy-intensive process industries from traditional heat-driven methods to innovative electrically-driven processes. This aims to significantly reduce Greenhouse Gas (GHG) emissions, achieve substantial energy savings, and enhance the economic viability and resilience of the European process industry. - Explicit identification of target recipient type: Legal entities operating within energy-intensive and process industries, as well as research organizations and universities contributing to industrial innovation. - SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC, targeting Energy-Intensive Industries, Process Industries, and Manufacturing. - Geographic scope: Projects with impact across the European industry, aligning with EU climate neutrality goals. Eligible participants are from EU Member States and countries associated with Horizon Europe, with a specific exclusion for entities established in China. - Key filtering criteria for initial grant screening: Projects must focus on electrically-driven technologies to replace heat input, demonstrate strong potential for GHG emission avoidance and at least 25% energy savings, and provide a clear business case for European deployment. - Grant frequency: This specific topic is part of the Horizon Europe Work Programme 2025 and is a single-stage call for proposals, with calls under the broader Horizon Europe framework occurring regularly.

Funding

Up to 10000000.00 EUR

Deadline

Sept. 23, 2025, midnight

Details

NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)

PAR-24-221

Programme: National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Program

This grant aims to support US small businesses in bridging the "Valley of Death" funding gap for neurological disease treatments, tools, and diagnostics. It targets small businesses that have previously received an NIH SBIR or STTR Phase II award, allowing them to pursue advanced clinical trials (Phase 1 or 2) or develop complex research tools towards commercialization. This is a SECTOR-SPECIFIC grant focused on neurological disorders and related medical biotechnology. Geographic scope is limited to the United States for eligible small business concerns, though project activities may include foreign components. Key filtering criteria include prior NIH SBIR/STTR Phase II funding, status as a US Small Business Concern, and focus on clinical trials or research tools for neurological conditions. This is a recurring grant opportunity with multiple application due dates until April 2027, reissued from a previous program.

Funding

Up to 3000000.00 USD

Deadline

April 5, 2027, 5 p.m.

Details

Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)

PAR-25-318

Programme: National Institute on Deafness and Other Communication Disorders (NIDCD) Research Grant Program

This grant aims to stimulate exploratory and developmental HIV/AIDS research focused on hearing, balance, taste, smell, voice, speech, and language disorders, specifically benefiting people living with HIV. The grant targets a wide range of organizations, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities, of unspecified size, capable of conducting research. This is a SECTOR-SPECIFIC grant with a global geographic scope. Key filtering criteria include: research must be HIV/AIDS related and fall within NIDCD's mission areas (communication disorders), must address high-priority NIH Office of AIDS Research (OAR) areas, and only low-risk clinical trials are supported. This is a recurring funding opportunity (reissue of PAR-23-106) for exploratory/developmental research (R21 activity code) within the National Institutes of Health (NIH) framework.

Funding

Up to 275000.00 USD

Deadline

Jan. 7, 2028, 5 p.m.

Details

Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

PAR-25-103

Programme: National Institutes of Health (NIH) - National Cancer Institute (NCI)

Core Objective: To facilitate well-planned clinical trials across the cancer prevention and control spectrum by supporting studies that acquire critical data to complete the protocol of a full-scale multi-center Phase II or later phase trial.
Target Recipient Type and Size: Open to a wide range of organizations including higher education institutions, nonprofits (both 501(c)(3) and others), for-profit organizations (including small businesses), local and federal governments, and non-domestic (foreign) entities. There are no explicit size restrictions, focusing on organizational capacity for clinical research planning.
SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC, focusing exclusively on cancer prevention and control clinical trials and related research activities.
Geographic Scope: Worldwide, as non-domestic (non-U.S.) entities are eligible to apply.
Key Filtering Criteria: The grant is for planning activities for future clinical trials, not for conducting full trials or early-stage mechanistic research. Applicants must have preliminary efficacy or effectiveness data for the future intervention already in existence. Proposals must include a detailed milestone plan and a description of the future clinical trial.
Grant Frequency and Program Context: This is a recurring funding opportunity with multiple application due dates extending through October 2027, reissued from a previous program (PAR-22-174). It is a U34 Planning Cooperative Agreement, intended to fill a gap in the NCI's funding mechanisms by supporting preparatory studies for robust clinical trials.

Funding

Up to 600000.00 USD

Deadline

Oct. 25, 2027, 5 p.m.

Details

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)

PAR-25-199

Programme: National Institutes of Health (NIH)

The core objective is to stimulate basic technology-focused research to develop next-generation human cell-derived Microphysiological Systems (MPS) and related assays.
These systems must replicate complex nervous system architectures and physiology with improved fidelity, enabling future studies of development, function, and aging in healthy and disease states.
Target recipients are research organizations capable of conducting exploratory/developmental biomedical and biobehavioral research.
This grant is SECTOR-SPECIFIC, focusing on the health and technology sectors, specifically neurobiology and bioengineering.
Geographic scope includes organizations within the United States and non-U.S. (foreign) entities globally.
Key filtering criteria for initial screening: must be focused on MPS technology development for nervous system research, not clinical trials, and not solely focused on compound screening or cell therapy.

Funding

Up to 275000.00 USD

Deadline

Oct. 16, 2025, 5 p.m.

Details

Improving the quality of life of persons with intellectual disabilities and their families

48340142TOPICSen

Programme: Horizon Europe

Single, clear statement of grant's core objective: To explore new ways to improve the quality of life, autonomy, and empowerment of persons with intellectual disabilities and their families by developing and implementing innovative medical, technological, and digital solutions, including habilitation and rehabilitation approaches.
Explicit identification of target recipient type and size: Legal entities capable of performing Research and Innovation Actions (RIAs).
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Health, Medical, Technology, Social Sciences, Disability Support).
Geographic scope and any location requirements: Eligible countries are defined in Annex B of the Work Programme General Annexes. Specifically, legal entities established in the United States of America are eligible to receive Union funding.
Key filtering criteria for initial grant screening: Focus on improving quality of life for persons with intellectual disabilities and their families; development of innovative medical, technological, or digital solutions; emphasis on habilitation and rehabilitation; inclusion of social sciences and humanities (SSH) expertise.
Grant frequency and program context: Part of the Horizon Europe 2025 Work Programme, specifically within the 'Health' cluster and the 'Staying healthy in a rapidly changing society' destination.

Funding

Up to 8000000.00 EUR

Deadline

April 16, 2026, midnight

Details

Projects Peer Review Panel (PPRP) 2026 – UKRI

PPRP 2026

Programme: Projects Peer Review Panel (PPRP)

This grant, the Projects Peer Review Panel (PPRP) 2026, aims to fund large or complex research projects in highly specialized scientific fields. It's designed for UK-based research organizations that have been specifically invited to apply after successfully submitting a Statement of Interest (SoI). This is a SECTOR-SPECIFIC grant, focusing primarily on areas like particle physics, nuclear physics, astronomy, particle astrophysics, accelerator physics, and computing for the PPAN Programme. The grant operates on a recurring basis, with frequent PPRP rounds, forming a core part of the Science and Technology Facilities Council (STFC) funding landscape. The key filtering criteria for initial screening are the requirement for an invitation following a successful SoI, and being an eligible UK research organization focused on the specified scientific domains.

Funding

Up to None GBP

Deadline

Aug. 27, 2026, 4 p.m.

Details

DFG, German Research Foundation - Priority Programmes

Priority Programmes

Programme: DFG, German Research Foundation - Priority Programmes

This grant, the DFG Priority Programmes, aims to advance science and the humanities by funding new, important research topics through coordinated, multi-location projects. It seeks to foster impactful research, especially interdisciplinary work, by creating added value through networking and supporting early career researchers. The grant is SECTOR-AGNOSTIC regarding specific research fields, but is explicitly focused on scientific and humanities research. It targets research institutions and researchers primarily in Germany. This is a recurring grant program with annual opportunities to propose new Priority Programmes.

Funding

Up to None None

Deadline

Oct. 14, 2026, 11 p.m.

Details

Computing resources on the STFC DiRAC HPC facility (RAC18)

RAC18

Programme: STFC DiRAC HPC Facility

This opportunity, known as RAC18, is for UK research organisations within the STFC theory community to apply for and gain access to High Performance Computing (HPC) resources on the DiRAC facility. The core objective is to support world-leading research in specific scientific domains by providing essential computing power and storage. This is a SECTOR-SPECIFIC grant, targeting research in areas such as particle physics, nuclear physics, astrophysics, astronomy, cosmology, solar system physics, and particle astrophysics. The primary target recipients are UK-based research organisations, although overseas organisations approved by STFC may apply. Early career researchers, including postdocs and PhD students, are specifically encouraged to apply as project leads. This is an annual funding call for computing resources, with successful allocations beginning on April 1st, 2026.

Funding

Up to None None

Deadline

Sept. 18, 2025, 3 p.m.

Details

Bundesförderung für Energie- und Ressourceneffizienz in der Wirtschaft (Zuschuss) – Förderung von Transformationsplänen (Modul 5)

Modul 5

Programme: Bundesförderung für Energie- und Ressourceneffizienz in der Wirtschaft

Grant Purpose and Target This grant, known as the 'Bundesförderung für Energie- und Ressourceneffizienz in der Wirtschaft (Zuschuss) – Förderung von Transformationsplänen (Modul 5),' aims to support German businesses in their efforts to increase energy and resource efficiency and reduce greenhouse gas emissions. Specifically, Module 5 focuses on funding the creation of transformation plans to help companies achieve greenhouse gas neutrality through strategic investment projects.

Core Objective: To empower German companies to develop comprehensive strategies (transformation plans) for enhancing energy and resource efficiency and significantly reducing their greenhouse gas emissions.
Target Recipients: This grant is designed for companies (Unternehmen) of all sizes based in Germany. No specific size limitations are mentioned, making it accessible to startups, SMEs, and larger enterprises.
Sector Focus: This is a SECTOR-AGNOSTIC grant. While the focus is on energy and resource efficiency, which are critical in many industries, it is not restricted to a single sector. Businesses across various economic activities are encouraged to apply if their projects align with the grant's objectives.
Geographic Scope: The grant is applicable nationwide (bundesweit) within Germany. Projects and applicant organizations must be located within Germany.
Key Filtering Criteria for Initial Screening: Your business should be a German company actively planning or needing to develop a strategic transformation plan focused on achieving greenhouse gas neutrality and improving energy/resource efficiency. The application must be submitted before you start the actual project.
Grant Frequency and Program Context: This grant is part of a larger, ongoing federal funding program. It is a recurring opportunity, available until the end of 2028, indicating a long-term commitment to these goals within the German economy.